Author

Kai‐Bin C. Ooi

Observed names: Kai-Bin C Ooi, Kai-Bin Ooi, Kai‐Bin Ooi

Institution: Athira Pharma (United States)

Observed institution: Athira Pharma (United States)

ORCID: 0009-0000-4030-6790

Observed ORCID: 0009-0000-4030-6790

OpenAlex ID: A5026882916

Fosgonimeton Provides Congruent Improvements on Neurodegeneration Biomarkers, Significantly Correlating With Composite Clinical Score of Cognition and Function in Alzheimer’s Disease (S26.008)

2023 · Hans Moebius, Kai-Bin Ooi, et al. · Neurology · 3

ACT‐AD: Fosgonimeton in mild‐to‐moderate Alzheimer’s disease – first results of a randomized, placebo‐controlled, 26‐week Phase 2 proof‐of‐concept trial

2022 · Hans J. Moebius, Charles B. Bernick, et al. · Alzheimer s & Dementia · 3

Biomarker analyses from the phase 2, randomized, placebo‐controlled ACT‐AD and open‐label extension clinical trials of fosgonimeton in patients with mild‐to‐moderate Alzheimer’s disease

2023 · Hans J. Moebius, Kai‐Bin C. Ooi, et al. · Alzheimer s & Dementia · 1

Fosgonimeton in mild-to-moderate Alzheimer's disease

2025 · Anton P Porsteinsson, Marwan Sabbagh, et al. · Journal of Alzheimer s Disease Reports

Works count: 4

Citation count: 7

H-index: 2

I10-index: